Humira (adalimumab) does not make your skin burn more easily the way certain antibiotics or acne medications do, but it does shift the balance of risk when it comes to sun exposure. By blocking tumor necrosis factor-alpha (TNF-alpha), a protein your immune system relies on to identify and destroy damaged cells, Humira can weaken one of the body’s natural defenses against UV-induced skin changes. The practical result is a modestly elevated risk of certain skin cancers and, in rare cases, unusual photosensitivity reactions that can mimic autoimmune skin disease.
Why a TNF Blocker Changes the Way Your Skin Handles UV
When ultraviolet light hits your skin, one of the first things your body does is ramp up production of TNF-alpha. Research on human skin cells has shown that UV exposure triggers a dramatic spike in TNF-alpha, with the molecule’s messenger RNA increasing by roughly 20- to 40-fold within four hours and its protein levels staying elevated for at least 48 hours afterward.1Journal of Investigative Dermatology. Post-transcriptional regulation of UV induced TNF-alpha expression That surge is not just an inflammatory alarm. TNF-alpha also helps your immune system flag UV-damaged skin cells for destruction before they can accumulate mutations and potentially turn cancerous.
Humira works by neutralizing TNF-alpha throughout the body, which is exactly why it helps control conditions like rheumatoid arthritis, psoriasis, and Crohn’s disease. But that same suppression means the skin’s post-UV cleanup crew is operating with reduced resources. A broad review of immunosuppressive therapies noted that immunosuppression in general appears to increase skin cancer risk in a manner that depends on how much sun exposure a person gets.2PubMed Central. Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence In other words, the combination of UV damage and reduced immune surveillance is what creates the problem, not either one alone.
Non-Melanoma Skin Cancer Risk on Humira
The best-studied concern is non-melanoma skin cancer, which includes basal cell carcinoma and squamous cell carcinoma. A meta-analysis pooling data from studies of patients with rheumatoid arthritis, psoriasis, and inflammatory bowel disease found that people on biologic therapies had roughly a 25 percent higher risk of developing non-melanoma skin cancer compared to those not on biologics. The risk was similar in rheumatoid arthritis and psoriasis patients, though it did not reach statistical significance in the smaller group of inflammatory bowel disease patients.3PubMed Central. Risk of non-melanoma skin cancer with biological therapy in common inflammatory diseases: a systemic review and meta-analysis When broken down by type, the increase applied to both basal cell and squamous cell cancers, with squamous cell showing a somewhat larger relative jump.
A large cohort study of veterans with rheumatoid arthritis put the risk increase in sharper terms, finding that patients on TNF-alpha blockers had about a 42 percent higher likelihood of developing non-melanoma skin cancer compared to those on older, non-biologic disease-modifying drugs.4Rheumatology. Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis That sounds alarming as a percentage, but the absolute numbers matter here. In a screening program that followed several hundred patients on biologics for an average of five years, the actual incidence was about 10 cases of non-melanoma skin cancer per 1,000 patient-years, with most of those being basal cell carcinomas that were cured by straightforward surgical removal with no recurrence.5Annales de Dermatologie et de Vénéréologie. Systematic skin cancer screening in patients treated with biologics for chronic inflammatory rheumatic diseases: an 11-year experience So while the relative risk is real and consistent across studies, the chance of any individual patient developing one of these cancers in a given year remains fairly low.
What the Evidence Says About Melanoma
Melanoma is the skin cancer people worry about most, and the data here are more reassuring than for non-melanoma types. A systematic review and meta-analysis published in JAMA Dermatology found that rheumatoid arthritis patients treated exclusively with TNF inhibitors showed no statistically significant increase in melanoma risk compared to those on conventional therapies.6JAMA Dermatology. Melanoma Risk in Patients Treated With Biologic Therapy for Common Inflammatory Diseases: A Systematic Review and Meta-analysis The same screening program that tracked non-melanoma cases found melanomas at an incidence of about 3.7 per 1,000 patient-years, and exposure to biologics was not significantly associated with melanoma occurrence after adjusting for other factors.7Annales de Dermatologie et de Vénéréologie. Systematic skin cancer screening in patients treated with biologics for chronic inflammatory rheumatic diseases: an 11-year experience
That said, case reports do exist. One well-documented case involved a 54-year-old woman who developed a primary melanoma during adalimumab treatment for severe Crohn’s disease.8PubMed Central. Development of primary malignant melanoma during treatment with a TNF-α antagonist for severe Crohn’s disease: a case report and review of the hypothetical association between TNF-α blockers and cancer Individual cases cannot establish causation, but they are part of why dermatologists recommend regular skin checks for anyone on long-term TNF-blocker therapy. The bottom line from the pooled data is that melanoma risk, if it exists at all on TNF inhibitors, appears much smaller than the non-melanoma signal.
Drug-Induced Photosensitivity and Lupus-Like Reactions
Separate from the skin cancer question, a small number of people on adalimumab develop an unexpected sensitivity to sunlight that can resemble lupus. In one reported case, a 40-year-old woman with rheumatoid arthritis developed facial redness in a butterfly pattern across her nose and cheeks, painless mouth ulcers, and chilblain-like lesions on both ears after her third dose of adalimumab. The symptoms were consistent with drug-induced lupus erythematosus and appeared to be triggered or worsened by sun exposure.9Postgraduate Medical Journal. Adalimumab-induced photosensitivity and oral erosions in rheumatoid arthritis
This type of reaction is rare, but it may be underrecognized. An analysis of the FDA’s adverse event reporting database identified adalimumab as having a novel signal for drug-induced photosensitivity, noting that while the drug was already known to cause lupus-like symptoms, photosensitivity had not been listed as an adverse reaction on the drug label.10Scientific Reports. Causes of drug-induced photosensitivity: an analysis using FDA adverse event reporting system database UV radiation is also a well-established trigger for cutaneous lupus in general, so people who are genetically susceptible to lupus-spectrum conditions may find that the combination of adalimumab and sun exposure unmasks something that would otherwise have stayed quiet.11Lupus. Trigger factors of cutaneous lupus erythematosus: a review of current literature
If you notice new facial rashes, unexplained mouth sores, or skin that reacts to sunlight in ways it never did before starting Humira, those symptoms deserve a dermatology evaluation rather than a wait-and-see approach. Drug-induced lupus typically resolves after the medication is stopped, but catching it early prevents unnecessary discomfort and scarring.
Why Your Underlying Condition Changes the Picture
Not everyone on Humira faces the same level of sun-related skin cancer risk, and the condition being treated makes a real difference. A study directly comparing psoriasis patients to rheumatoid arthritis patients on TNF inhibitors found a striking gap: psoriasis patients had roughly six times the risk of developing non-melanoma skin cancer and reached their first diagnosis sooner.12PubMed. An increased risk of non-melanoma skin cancer during TNF-inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease-related factors The researchers attributed the difference mainly to disease-related factors rather than the drug itself. Many psoriasis patients have previously undergone UV-based phototherapy, which accumulates DNA damage over time, and some have histories of other immunosuppressive treatments like cyclosporine or methotrexate that compound the effect.
Meanwhile, the meta-analysis mentioned earlier found that patients with inflammatory bowel disease on biologics did not show a statistically significant increase in non-melanoma skin cancer risk.13PubMed Central. Risk of non-melanoma skin cancer with biological therapy in common inflammatory diseases: a systemic review and meta-analysis The numbers were too small to draw firm conclusions, but the trend suggests that IBD patients without a history of extensive UV exposure or additional immunosuppression may face a lower baseline risk from sun exposure while on Humira. Your rheumatologist or dermatologist can factor in your personal treatment history when advising how aggressive your sun protection needs to be.
How Newer Biologics Compare
If you are on Humira and concerned about skin cancer risk, you may wonder whether switching to a different biologic would reduce that risk. There is emerging evidence that it could. A recent analysis found that patients treated with newer classes of biologics, specifically those targeting interleukin-17 or interleukin-23, had a lower risk of non-melanoma skin cancer compared to those on TNF-alpha inhibitors like adalimumab.14PubMed. Decreased Nonmelanoma Skin Cancer Risk With Interleukin-17 and Interleukin-23 Inhibitors Versus TNF-α Inhibitors in Psoriasis These newer drugs work through different immune pathways that may preserve more of the skin’s natural tumor surveillance.
This does not mean everyone on Humira should switch. TNF inhibitors have decades of real-world safety data, and for many patients they remain the best option for controlling their inflammatory disease. But for someone who already has a personal history of skin cancer, extensive prior sun damage, or a treatment history that includes phototherapy, the conversation about alternatives becomes more relevant. It is the kind of decision that involves weighing disease control, insurance access, and individual risk factors, not a blanket recommendation.
Children and Adolescents on TNF Inhibitors
Humira is approved for several pediatric conditions, including juvenile idiopathic arthritis and pediatric Crohn’s disease, which means some parents face questions about sun exposure for kids on the drug. The pediatric data are thinner than the adult data, and what exists is somewhat reassuring. A review of long-term safety data for immunomodulators in children concluded that the overall cancer risk associated with treatment appears non-significant in pediatric populations, though it recommended careful individual risk assessment before starting aggressive biologic therapy.15PubMed. Long-term safety of immunomodulators in pediatric inflammatory diseases
A separate study specifically tracking malignancies in children on TNF inhibitors identified 15 cancers, of which two were malignant melanomas.16PubMed Central. Risk of Malignancy Associated with Pediatric Use of Tumor Necrosis Factor Inhibitors Two melanomas among a large population of treated children is a small number, but it stands out because melanoma is uncommon in pediatric patients generally. Children who spend more time outdoors and may be less diligent about sunscreen already accumulate UV damage faster than adults realize, so building good sun protection habits early matters for any child on a TNF blocker.
Practical Sun Protection on Humira
Given the evidence, sun protection while on Humira does not require dramatic lifestyle changes, but it does warrant being more deliberate than you might otherwise be. The essentials are familiar but become genuinely important rather than optional when your immune surveillance is pharmacologically dampened.
- Broad-spectrum sunscreen: SPF 30 or higher, reapplied every two hours during continuous outdoor exposure. Water-resistant formulas matter if you swim or sweat heavily. Physical (mineral) sunscreens with zinc oxide or titanium dioxide are effective and tend to be well tolerated by people with sensitive or inflamed skin.
- Protective clothing: UPF-rated shirts and wide-brimmed hats do more than sunscreen alone, particularly for people who forget to reapply. Tightly woven dark fabrics block more UV than light, loosely woven ones.
- Peak hours: UV intensity is highest between about 10 a.m. and 4 p.m. in most locations during warmer months. Seeking shade during this window makes the biggest single difference.
- Annual skin checks: The screening study that tracked biologic-treated patients for over a decade caught cancers at treatable stages because patients were examined regularly.17Annales de Dermatologie et de Vénéréologie. Systematic skin cancer screening in patients treated with biologics for chronic inflammatory rheumatic diseases: an 11-year experience A full-body skin exam by a dermatologist once a year is a reasonable baseline for anyone on long-term TNF-blocker therapy, and more often if you have a personal or family history of skin cancer.
- Self-monitoring: Between professional exams, watch for new moles, existing moles that change in size or color, sores that do not heal within a few weeks, or scaly patches that persist. Squamous cell carcinomas in particular can look like rough, crusty spots that are easy to dismiss as dry skin.
You do not need to avoid the outdoors entirely. The immunosuppressive effect of Humira is much milder than what organ transplant recipients experience, and those patients live normal lives with sensible precautions. The goal is consistent, reasonable protection rather than fear of sunlight. If you notice unusual skin reactions after starting Humira, particularly any rash in sun-exposed areas, facial redness that follows a butterfly pattern, or new mouth sores, bring those to your doctor’s attention promptly rather than writing them off as sunburn or coincidence.